Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
Genetic Technologies Provides Update on COVID-19 Disease Severity Test
Published: 2020-07-15 (Crawled : 22:16) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 22.57%
H: 271.84%
C: 104.69%
covid test disease technology covid-19
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
PHIO | $0.631 -1.07% -1.08% 29K
|
Health Technology
|
| O: -2.94%
H: 175.0%
C: 167.05%
ph-894 disease positive ph94
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease
Published: 2023-07-20 (Crawled : 13:00) - biospace.com/
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: 0.0%
H: 147.25%
C: 119.78%
disease
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Published: 2021-11-18 (Crawled : 12:13) - globenewswire.com
LGVN 1 d | $1.93 -3.98% -4.15% 460K
|
|
| O: 27.4%
H: 139.24%
C: 84.68%
disease food rare pediatric disease designation heart drug lomecel-b designation rare
Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study
Published: 2021-02-02 (Crawled : 14:01) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 45.24%
H: 123.12%
C: 66.04%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
Published: 2022-12-05 (Crawled : 14:20) - biospace.com/
CPHI | $0.3158 -3.63% 4.88% 440K
|
Health Technology
|
| O: 15.15%
H: 89.15%
C: 25.38%
acquisition pharma device disease eye china
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
Published: 2023-07-13 (Crawled : 14:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 16.14%
H: 88.0%
C: 4.0%
disease world presentation international research alzheimer's benefits
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model
Published: 2022-07-12 (Crawled : 15:00) - prnewswire.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -0.57%
H: 74.4%
C: 3.19%
disease alzheimer's therapeutics ht-alz
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 11.05%
H: 71.96%
C: 40.74%
rgls8429 treatment fda drug disease kidney application therapeutics
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Published: 2021-08-10 (Crawled : 13:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 58.58%
H: 67.22%
C: 42.09%
disease phase 1 positive results trial phase 2 phase 3
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
CI | $352.39 1.04% 0.0% 1.3M
|
Health Services
|
| O: 0.43%
H: 0.0%
C: -2.53%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer treatment fda approval alzheimer’s alzheimer's disease alzheimer's
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
Published: 2022-10-25 (Crawled : 16:00) - biospace.com/
REVB | $2.06 -8.04% -8.74% 43K
|
|
| O: 28.83%
H: 55.86%
C: 27.76%
disease preclinical kidney positive results
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Published: 2023-09-06 (Crawled : 13:00) - globenewswire.com
PALI | $4.735 -6.61% -7.07% 140K
|
Manufacturing
|
| O: 79.79%
H: 55.65%
C: 16.13%
drug disease worldwide pipeline agreement
XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical TrialBridging Pharmacokinetics Study Part 1 Recruitment Completed for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 28.45%
H: 53.69%
C: 22.82%
oxy-101 disease kidney program
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
Published: 2022-01-04 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 61.79%
H: 53.51%
C: 14.04%
alzheimer therapeutics disease positive results positive results alzheimer’s alzheimer's disease alzheimer's ht-alz
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Published: 2022-03-31 (Crawled : 12:00) - globenewswire.com
LGVN 1 d | $1.93 -3.98% -4.15% 460K
|
|
| O: 39.73%
H: 51.65%
C: 46.96%
dementia disease trial results alzheimer’s lomecel-b alzheimer's disease alzheimer's phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.